GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 50

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016', provides in depth analysis on GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted pipeline therapeutics.

The report provides comprehensive information on the GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)

- The report reviews GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics and enlists all their major and minor projects

- The report assesses GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Overview 7
Therapeutics Development 8
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Products under Development by Stage of Development 8
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Products under Development by Therapy Area 9
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Products under Development by Indication 10
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Products Glance 11
Early Stage Products 11
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Products under Development by Companies 12
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Products under Development by Universities/Institutes 14
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Companies Involved in Therapeutics Development 21
Aurigene Discovery Technologies Limited 21
Boehringer Ingelheim GmbH 22
Horizon Discovery Group Plc 23
Nimbus Therapeutics, LLC 24
Nuevolution AB 25
PeptiDream Inc. 26
Tosk, Inc. 27
Warp Drive Bio, Inc. 28
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Drug Profiles 29
ARS-853 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AZD-4785 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
HD-001 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
MM-41 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Inhibit KRAS for Oncology - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules 1 to Inhibit K-Ras for Oncology - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules 2 to Inhibit K-Ras for Oncology - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules 3 to Inhibit Ki-Ras for Oncology - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Inhibit K-Ras for Oncology - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Inhibit K-Ras for Oncology - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Inhibit KRAS for Oncology - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit KRas for Solid Tumor - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Inhibit KRAS2B for Oncology - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
SML-8731 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Vaccine to Target K-RAS for Lung Cancer - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Dormant Projects 46
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Featured News & Press Releases 47
Jul 29, 2014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation 47
May 08, 2013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement 47
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Aurigene Discovery Technologies Limited, H2 2016 21
Pipeline by Boehringer Ingelheim GmbH, H2 2016 22
Pipeline by Horizon Discovery Group Plc, H2 2016 23
Pipeline by Nimbus Therapeutics, LLC, H2 2016 24
Pipeline by Nuevolution AB, H2 2016 25
Pipeline by PeptiDream Inc., H2 2016 26
Pipeline by Tosk, Inc., H2 2016 27
Pipeline by Warp Drive Bio, Inc., H2 2016 28
Dormant Projects, H2 2016 46

List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Molecule Types, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 19
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Efficacy of Stand-alone Power Sources Drive The Global Distributed Energy Generation Market
    The global market for distributed energy generation is expected to magnify at a momentous CAGR of 11.4% between 2016 and 2020. The small-scale generation of electricity, oscillating from a few kilowatts to multitudes of megawatts, is denoted as distributed energy generation. In this process, power is usually produced using renewable resources or by generators during consumption. [...]
  • Global Organic Food Market Makes A Mark in Developed Economies
    Buyers throughout the world are becoming more and more health cognizant, which has occasioned in an alteration in their palates and inclinations. The global organic food market was worth US$88.1 billion in 2015 is anticipated to record a CAGR of over 16% between 2015 and 2020. Amongst the various different food products available, the fruits [...]
  • Top 10 Cellular Analysis Market by Technology (Imaging, PCR, Flow Cytometry, High-content Screening, Blotting, Spectrophotometry), Application (Stem Cell, Cancer, Tissue Engineering) & End User (Biotechnology, Research) - Global Forecast to 2021
    Published: 19-Jan-2017        Price: US 5650 Onwards        Pages: 178
    The top 10 cellular analysis market is expected to reach USD 41.34 billion by 2021 from USD 28.66 billion in 2016, at a CAGR of 7.6% during the forecast period. Factors such as increasing government support in the form of funding in cell biology-based research, growing biotechnology industry, increasing prevalence of chronic and infectious diseases, and rising number of cancer cases are driving the growth of the top 10 cellular analysis market. The top 10 cellular analysis market is c......
  • Transfection Reagents and Equipment Market by Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral)), Application (Biomedical, Protein Production), End User - Global Forecast to 2021
    Published: 13-Jan-2017        Price: US 5650 Onwards        Pages: 209
    The global transfection reagents and equipment market is expected to reach USD 1.02 billion by 2021 from USD 715.4 million in 2016, at a CAGR of 7.5% during the forecast period 2016 to 2021. Over the years, the transfection reagents and equipment market has witnessed various technological advancements in equipment as well as reagents to address the requirements of researchers and biotechnology & biopharmaceutical companies. These advancements have led to the development of transfe......
  • Rat Model Market by Model Type (Outbred, Inbred, Knockout), Technology (CRISPR, Micro Injection), Therapeutic Area (Neurology, Oncology), Service (Breeding, Cryopreservation), Care Products (Cages, Feed, Bedding) & End User -Global Forecast to 2021
    Published: 12-Jan-2017        Price: US 5650 Onwards        Pages: 253
    The rat model market is projected to reach USD 588.9 million by 2021 from USD 387.7 million in 2016, growing at a CAGR of 8.7% during the forecast period.Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. In addition to this, increase in R&D activities in pharmaceutical industries is further stimulating the market growth.......
  • Global Mycoplasma Testing Market Research Report 2017
    Published: 10-Jan-2017        Price: US 2999 Onwards        Pages: 116
    This report studies Mycoplasma Testing in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Abbott Affymetrix Beckman Coulter/Danaher Becton Dickinson BioMerieux Bio-Rad Cepheid Diamedix/Erba DiaSorin Eiken Chemical Elitech Group Enzo B......
  • Sphingosine 1-Phosphate (S1P) Receptor Agonists -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Sphingosine 1-Phosphate (S1P) Receptor Agonists-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Sphingosine 1-Phosphate (S1P) Receptor Agonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activit......
  • Sphingosine 1-Phosphate Type 1 (S1P-1) Receptor Agonists -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Sphingosine 1-Phosphate Type 1 (S1P-1) Receptor Agonists-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Sphingosine 1-Phosphate Type 1 (S1P-1) Receptor Agonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other d......
  • Inositol 5'-Phosphatase (SHIP) Agonists -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Inositol 5'-Phosphatase (SHIP) Agonists-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Inositol 5'-Phosphatase (SHIP) Agonists. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including te......
  • Insulin Like Growth Factor 1 (IGF-1) Activators -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Insulin Like Growth Factor 1 (IGF-1) Activators-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Insulin Like Growth Factor 1 (IGF-1) Activators. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activit......
  • Insulin Like Growth Factor 2 (IGF-2) Inhibitors -Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Insulin Like Growth Factor 2 (IGF-2) Inhibitors-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Insulin Like Growth Factor 2 (IGF-2) Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activit......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs